Seaport Therapeutics, Inc.

Ce a raportat Seaport Therapeutics, Inc. la 3 august 2026

Din raportul 8-K al companiei.

Conferințe de rezultate

Pentru Seaport Therapeutics, Inc. nu este disponibilă nicio transcriere a unei conferințe de rezultate.

Ce a spus conducerea

“The second quarter of 2026 was marked by two major milestones for Seaport – positive results from our Phase 1 proof-of-concept trial of GlyphAgo and the successful completion of our IPO,”

Citat cuvânt cu cuvânt din comunicat și afișat doar atunci când raportarea îl atribuie unei persoane numite.

Cum a reacționat prețul

Comunicatele apar după închidere sau înainte de deschidere, deci mișcarea este cea a ședinței următoare.

Cu ce se ocupă Seaport Therapeutics, Inc.

Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph TM platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families.

Descrierea proprie a companiei, așa cum apare la finalul comunicatului.